Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 5, 2017 (9 years ago)

Urin D/S Tablets Methenamine 81.6 mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Superpotent Drug: Subpotent Drug. FDA analysis found this product to be Out of Specification for assay which could result in either Subpotent and/or Superpotent tablets.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Urin D/S Tablets Methenamine 81.6 mg, Sodium Biphosphate 40.8 mg, Phenyl Salicylate 36.2 mg, Methylene Blue 10.8 mg, Hyoscyamine Sulfate 0.12 mg, Rx Only, 100-count bottle, Manufactured For: Llorens Pharmaceutical Corp., International Division, Miami, FL 33166. NDC: 54859-701-10

Affected NDC 54859-0701-10

Compare with the code on your package — it is the most precise check available.

Drug: Hyoscyamine

Recalling firm
Llorens Pharmaceutical Corp.
Origin
PR, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0081-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hyoscyamine recalls

See all
Class II · Moderate risk

Levsin injection

CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

Terminated cGMP deviation Viatris Inc NDC 0037-9001-05 D-0866-2023
Class II · Moderate risk

Vilamit Mb

cGMP deviations

Terminated cGMP deviation Vilvet Pharmaceuticals Inc. NDC 71186-002-35 D-1487-2020

Other wrong potency / content recalls from 2017

All wrong potency / content recalls
Class II · Moderate risk

Viokace (pancrelipase)

Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

Terminated Wrong potency / content Allergan NDC 58914-117-10 D-0154-2018